417 related articles for article (PubMed ID: 32799550)
1. New Therapeutic Options for Advanced Hepatocellular Carcinoma.
Ma YS; Liu JB; Wu TM; Fu D
Cancer Control; 2020; 27(3):1073274820945975. PubMed ID: 32799550
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
3. Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.
Wang T; Zhang Q; Wang N; Liu Z; Zhang B; Zhao Y
Curr Med Chem; 2021; 28(16):3107-3146. PubMed ID: 33050856
[TBL] [Abstract][Full Text] [Related]
4. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
5. [Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
Lai JM; Hu S; Lin H; Luo H; Luo YB
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):406-409. PubMed ID: 31216824
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.
Guardascione M; Toffoli G
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878115
[TBL] [Abstract][Full Text] [Related]
7. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
Liu L; Qin S; Zhang Y
Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
[TBL] [Abstract][Full Text] [Related]
8. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in hepatocellular carcinoma.
Bronte F; Bronte G; Cusenza S; Fiorentino E; Rolfo C; Cicero G; Bronte E; Di Marco V; Firenze A; Angarano G; Fontana T; Russo A
Curr Med Chem; 2014; 21(8):966-74. PubMed ID: 23992323
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
11. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
Moriguchi M; Umemura A; Itoh Y
Clin J Gastroenterol; 2016 Aug; 9(4):184-90. PubMed ID: 27401471
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update.
Kudo M
Oncology; 2017; 93 Suppl 1():135-146. PubMed ID: 29258077
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
Li SQ; Yang Y; Ye LS
World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
[TBL] [Abstract][Full Text] [Related]
14. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma.
Ferrarese A; Sciarrone SS; Pellone M; Shalaby S; Battistella S; Zanetto A; Germani G; Russo FP; Senzolo M; Burra P; Gambato M
Minerva Gastroenterol (Torino); 2021 Mar; 67(1):4-10. PubMed ID: 33222429
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Harding JJ
Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
18. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma.
Chen X; Kou L; Xie X; Su S; Li J; Li Y
Immunology; 2024 May; 172(1):21-45. PubMed ID: 38214111
[TBL] [Abstract][Full Text] [Related]
19. Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM; Montal R; Sia D; Finn RS
Nat Rev Clin Oncol; 2018 Oct; 15(10):599-616. PubMed ID: 30061739
[TBL] [Abstract][Full Text] [Related]
20. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.
Pinter M; Jain RK; Duda DG
JAMA Oncol; 2021 Jan; 7(1):113-123. PubMed ID: 33090190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
